HRP20120440T1 - Inhibitori virusa hepatitisa c - Google Patents
Inhibitori virusa hepatitisa c Download PDFInfo
- Publication number
- HRP20120440T1 HRP20120440T1 HRP20120440AT HRP20120440T HRP20120440T1 HR P20120440 T1 HRP20120440 T1 HR P20120440T1 HR P20120440A T HRP20120440A T HR P20120440AT HR P20120440 T HRP20120440 T HR P20120440T HR P20120440 T1 HRP20120440 T1 HR P20120440T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- hcv
- imidazol
- propanediyl
- compound
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 3
- 241000711549 Hepacivirus C Species 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 22
- 239000000203 mixture Substances 0.000 claims abstract 7
- 208000015181 infectious disease Diseases 0.000 claims abstract 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 6
- 108010047761 Interferon-alpha Proteins 0.000 claims 6
- 102000006992 Interferon-alpha Human genes 0.000 claims 6
- 108010050904 Interferons Proteins 0.000 claims 6
- 102000014150 Interferons Human genes 0.000 claims 6
- 229940079322 interferon Drugs 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 229960000329 ribavirin Drugs 0.000 claims 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 229960000888 rimantadine Drugs 0.000 claims 2
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 229930010555 Inosine Natural products 0.000 claims 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 1
- 108050006182 Inosine-5'-monophosphate dehydrogenases Proteins 0.000 claims 1
- 102000016600 Inosine-5'-monophosphate dehydrogenases Human genes 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003786 inosine Drugs 0.000 claims 1
- FFWMVKRMKVFJPB-YFRBGRBWSA-N methyl N-[(2R)-1-[[(1R)-1-[5-[4-[4-[2-[(1R)-1-[[(2R)-2-(methoxycarbonylamino)-3-methylbutanoyl]amino]-2-methylpropyl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]-2-methylpropyl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N1C([C@@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)OC)=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H](NC(=O)[C@H](NC(=O)OC)C(C)C)C(C)C)=C1 FFWMVKRMKVFJPB-YFRBGRBWSA-N 0.000 claims 1
- FFWMVKRMKVFJPB-PSWJWLENSA-N methyl N-[(2R)-1-[[(1S)-1-[5-[4-[4-[2-[(1S)-1-[[(2R)-2-(methoxycarbonylamino)-3-methylbutanoyl]amino]-2-methylpropyl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]-2-methylpropyl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N1C([C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)OC)=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@@H](NC(=O)[C@H](NC(=O)OC)C(C)C)C(C)C)=C1 FFWMVKRMKVFJPB-PSWJWLENSA-N 0.000 claims 1
- FFWMVKRMKVFJPB-WZJLIZBTSA-N methyl N-[(2S)-1-[[(1R)-1-[5-[4-[4-[2-[(1R)-1-[[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]amino]-2-methylpropyl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]-2-methylpropyl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N1C([C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)OC)=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H](NC(=O)[C@@H](NC(=O)OC)C(C)C)C(C)C)=C1 FFWMVKRMKVFJPB-WZJLIZBTSA-N 0.000 claims 1
- FFWMVKRMKVFJPB-CUPIEXAXSA-N methyl N-[(2S)-1-[[(1S)-1-[5-[4-[4-[2-[(1S)-1-[[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]amino]-2-methylpropyl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]-2-methylpropyl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N1C([C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)OC)=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@@H](NC(=O)[C@@H](NC(=O)OC)C(C)C)C(C)C)=C1 FFWMVKRMKVFJPB-CUPIEXAXSA-N 0.000 claims 1
- IVGARYBJXSMBOU-OBMDHMNCSA-N methyl N-[(2S)-1-[[(1S)-1-[5-[4-[4-[2-[(1S)-1-[[(2S)-2-(methoxycarbonylamino)propanoyl]amino]-2-methylpropyl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]-2-methylpropyl]amino]-1-oxopropan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H](NC(=O)[C@H](C)NC(=O)OC)C(C)C IVGARYBJXSMBOU-OBMDHMNCSA-N 0.000 claims 1
- PEPHSVSAIPQVPT-ANFUHZJESA-N methyl N-[(2S)-4-methoxy-1-[[(1S)-1-[5-[4-[4-[2-[(1S)-1-[[(2S)-4-methoxy-2-(methoxycarbonylamino)butanoyl]amino]-2-methylpropyl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]-2-methylpropyl]amino]-1-oxobutan-2-yl]carbamate Chemical compound N1C([C@H](C(C)C)NC(=O)[C@@H](NC(=O)OC)CCOC)=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@@H](NC(=O)[C@H](CCOC)NC(=O)OC)C(C)C)=C1 PEPHSVSAIPQVPT-ANFUHZJESA-N 0.000 claims 1
- MYMIJQCZJSIYEF-PVDPSSSFSA-N methyl N-[(2S,3R)-3-methoxy-1-[[(1S)-1-[5-[4-[4-[2-[(1S)-1-[[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]amino]-2-methylpropyl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]-2-methylpropyl]amino]-1-oxobutan-2-yl]carbamate Chemical compound N1C([C@H](C(C)C)NC(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@@H](NC(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C(C)C)=C1 MYMIJQCZJSIYEF-PVDPSSSFSA-N 0.000 claims 1
- IVGARYBJXSMBOU-PDNQGOMLSA-N methyl n-[(2s)-1-[[(1r)-1-[5-[4-[4-[2-[(1r)-1-[[(2s)-2-(methoxycarbonylamino)propanoyl]amino]-2-methylpropyl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]-2-methylpropyl]amino]-1-oxopropan-2-yl]carbamate Chemical compound N1C([C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)OC)=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H](NC(=O)[C@H](C)NC(=O)OC)C(C)C)=C1 IVGARYBJXSMBOU-PDNQGOMLSA-N 0.000 claims 1
- PEPHSVSAIPQVPT-XITCCLNHSA-N methyl n-[(2s)-4-methoxy-1-[[(1r)-1-[5-[4-[4-[2-[(1r)-1-[[(2s)-4-methoxy-2-(methoxycarbonylamino)butanoyl]amino]-2-methylpropyl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]-2-methylpropyl]amino]-1-oxobutan-2-yl]carbamate Chemical compound N1C([C@@H](C(C)C)NC(=O)[C@@H](NC(=O)OC)CCOC)=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H](NC(=O)[C@H](CCOC)NC(=O)OC)C(C)C)=C1 PEPHSVSAIPQVPT-XITCCLNHSA-N 0.000 claims 1
- MYMIJQCZJSIYEF-DLKACNDSSA-N methyl n-[(2s,3r)-3-methoxy-1-[[(1r)-1-[5-[4-[4-[2-[(1r)-1-[[(2s,3r)-3-methoxy-2-(methoxycarbonylamino)butanoyl]amino]-2-methylpropyl]-1h-imidazol-5-yl]phenyl]phenyl]-1h-imidazol-2-yl]-2-methylpropyl]amino]-1-oxobutan-2-yl]carbamate Chemical compound N1C([C@@H](C(C)C)NC(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H](NC(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)C(C)C)=C1 MYMIJQCZJSIYEF-DLKACNDSSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 150000004074 biphenyls Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/053638 WO2009102318A1 (fr) | 2008-02-12 | 2008-02-12 | Inhibiteurs du virus de l'hépatite c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120440T1 true HRP20120440T1 (hr) | 2012-06-30 |
Family
ID=39944252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120440AT HRP20120440T1 (hr) | 2008-02-12 | 2012-05-23 | Inhibitori virusa hepatitisa c |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP2250163B1 (fr) |
| JP (1) | JP5314053B2 (fr) |
| KR (1) | KR101468765B1 (fr) |
| CN (1) | CN101998952B (fr) |
| AT (1) | ATE551337T1 (fr) |
| AU (1) | AU2008350327B2 (fr) |
| BR (1) | BRPI0822335A2 (fr) |
| CA (1) | CA2715367C (fr) |
| CY (1) | CY1112848T1 (fr) |
| DK (1) | DK2250163T3 (fr) |
| EA (1) | EA018782B1 (fr) |
| ES (1) | ES2383388T3 (fr) |
| HK (1) | HK1144935A1 (fr) |
| HR (1) | HRP20120440T1 (fr) |
| IL (1) | IL207468A (fr) |
| MX (1) | MX2010008650A (fr) |
| NZ (1) | NZ587323A (fr) |
| PL (1) | PL2250163T3 (fr) |
| PT (1) | PT2250163E (fr) |
| SI (1) | SI2250163T1 (fr) |
| WO (1) | WO2009102318A1 (fr) |
| ZA (1) | ZA201005700B (fr) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2740195A1 (fr) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Composes antiviraux |
| WO2010075376A2 (fr) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Composés antiviraux |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| WO2010099527A1 (fr) | 2009-02-27 | 2010-09-02 | Enanta Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hépatite c |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8507522B2 (en) | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2419404B1 (fr) | 2009-04-15 | 2015-11-04 | AbbVie Inc. | Composes anti virale |
| NZ706236A (en) | 2009-05-13 | 2016-07-29 | Gilead Pharmasset Llc | Antiviral compounds |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| DK2455376T3 (en) | 2009-06-11 | 2015-03-02 | Abbvie Bahamas Ltd | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011009084A2 (fr) | 2009-07-16 | 2011-01-20 | Vertex Pharmaceuticals Incorporated | Analogues du benzimidazole pour le traitement ou la prévention des infections à flavivirus |
| CN102625700A (zh) * | 2009-07-23 | 2012-08-01 | 夏尔有限责任公司 | 加兰他敏氨基酸和肽前药及其用途 |
| WO2011028596A1 (fr) | 2009-09-04 | 2011-03-10 | Glaxosmithkline Llc | Composés chimiques |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011031904A1 (fr) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Inhibiteurs du virus de l'hépatite c |
| US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2011081918A1 (fr) | 2009-12-14 | 2011-07-07 | Enanta Pharmaceuticals, Inc | Inhibiteurs du virus de l'hépatite c |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2012006877A (es) | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
| CN104530079B (zh) * | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8785487B2 (en) | 2010-01-25 | 2014-07-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| CA2791630A1 (fr) | 2010-03-04 | 2011-09-09 | Enanta Pharmaceuticals, Inc. | Agents pharmaceutiques combinatoires au titre d'inhibiteurs de la replication du vhc |
| CA2794145A1 (fr) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues pour traiter ou prevenir les infections a flavivirus |
| EP2555622A4 (fr) | 2010-04-09 | 2013-09-18 | Enanta Pharm Inc | Inhibiteurs du virus de l'hépatite c |
| US20110312996A1 (en) * | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| WO2011154871A1 (fr) * | 2010-06-10 | 2011-12-15 | Pfizer Limited | Inhibiteurs du virus de l'hépatite c |
| AR081691A1 (es) | 2010-06-28 | 2012-10-10 | Vertex Pharma | Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus |
| WO2012006060A1 (fr) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Composés et méthodes de traitement ou de prévention d'infections à flavovirus |
| US20130157894A1 (en) * | 2010-07-16 | 2013-06-20 | Jin-Hua Sun | Methods to identify combinations of ns5a targeting compound that act synergistically to inhibit hepatitis c virus replication |
| WO2012021704A1 (fr) | 2010-08-12 | 2012-02-16 | Enanta Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hépatite c |
| US20120195857A1 (en) * | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2012024363A2 (fr) | 2010-08-17 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Composés et méthodes de traitement ou de prévention d'infections virales par des flaviviridae |
| EP2963034A1 (fr) | 2010-08-26 | 2016-01-06 | RFS Pharma, LLC. | Inhibiteurs puissants et sélectifs du virus de l'hépatite c |
| ES2701020T3 (es) | 2010-09-22 | 2019-02-20 | Alios Biopharma Inc | Nucleósidos azido y análogos nucleotídicos |
| CN103189371B (zh) | 2010-11-04 | 2015-04-01 | 施万生物制药研发Ip有限责任公司 | 丙型肝炎病毒抑制剂 |
| SG10201509456SA (en) | 2010-11-17 | 2015-12-30 | Gilead Pharmasset Llc | Antiviral compounds |
| WO2012087976A2 (fr) * | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Nouveaux inhibiteurs de la réplication du virus de l'hépatite c |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| EP2709455A4 (fr) | 2011-05-18 | 2014-11-05 | Enanta Pharm Inc | Procédés de préparation de l'acide 5-azaspiro[2.4]heptane-6-carboxylique et de ses dérivés |
| TW201317223A (zh) | 2011-07-26 | 2013-05-01 | Vertex Pharma | 噻吩化合物 |
| WO2013016499A1 (fr) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Procédés de préparation de composés du thiophène |
| WO2013021344A1 (fr) | 2011-08-08 | 2013-02-14 | Lupin Limited | Nouveaux dérivés de quercétine utiles comme agents antiviraux |
| WO2013030750A1 (fr) | 2011-09-01 | 2013-03-07 | Lupin Limited | Composés antiviraux |
| UA116087C2 (uk) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Композиція для лікування вірусу гепатиту c |
| PL3431477T3 (pl) | 2011-11-16 | 2021-04-06 | Gilead Pharmasset Llc | Skondensowane imidazoliloimidazole jako związki przeciwwirusowe |
| RU2621734C1 (ru) | 2011-12-28 | 2017-06-07 | Янссен Сайенсиз Айрлэнд Юси | Гетеробициклические производные в качестве ингибиторов hcv |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) * | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9073943B2 (en) | 2012-02-10 | 2015-07-07 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| KR20140119012A (ko) | 2013-01-31 | 2014-10-08 | 길리어드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
| US20150065439A1 (en) | 2013-02-28 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US20150023913A1 (en) * | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN105517574B (zh) * | 2013-07-09 | 2019-01-18 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂的组合产品 |
| ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
| WO2015103490A1 (fr) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Formes galéniques antivirales solides |
| CN104860931A (zh) * | 2014-02-21 | 2015-08-26 | 常州寅盛药业有限公司 | 丙肝病毒抑制剂及其制药用途 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| WO2016089814A1 (fr) | 2014-12-02 | 2016-06-09 | Concert Pharmaceuticals, Inc. | Analogues deutériés du daclatasvir |
| US9790207B2 (en) * | 2015-09-04 | 2017-10-17 | Alexandre Vasilievich Ivachtchenko | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods |
| US20220099637A1 (en) | 2018-12-04 | 2022-03-31 | Bristol-Myers Squibb Company | Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring |
| CN109456375B (zh) * | 2018-12-11 | 2019-10-22 | 枣庄学院 | 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法 |
| JP2024519910A (ja) | 2021-05-21 | 2024-05-21 | ギリアード サイエンシーズ， インコーポレイテッド | ジカウイルス阻害剤としての五環式誘導体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003261434A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| DE102004036971B4 (de) | 2004-07-30 | 2009-07-30 | Advanced Micro Devices, Inc., Sunnyvale | Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen |
| US8143288B2 (en) * | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2008
- 2008-02-12 DK DK08780411.8T patent/DK2250163T3/da active
- 2008-02-12 NZ NZ587323A patent/NZ587323A/en not_active IP Right Cessation
- 2008-02-12 EA EA201001276A patent/EA018782B1/ru not_active IP Right Cessation
- 2008-02-12 AT AT08780411T patent/ATE551337T1/de active
- 2008-02-12 KR KR1020107020257A patent/KR101468765B1/ko not_active IP Right Cessation
- 2008-02-12 BR BRPI0822335A patent/BRPI0822335A2/pt not_active IP Right Cessation
- 2008-02-12 AU AU2008350327A patent/AU2008350327B2/en not_active Ceased
- 2008-02-12 PL PL08780411T patent/PL2250163T3/pl unknown
- 2008-02-12 WO PCT/US2008/053638 patent/WO2009102318A1/fr active Application Filing
- 2008-02-12 EP EP08780411A patent/EP2250163B1/fr not_active Not-in-force
- 2008-02-12 MX MX2010008650A patent/MX2010008650A/es active IP Right Grant
- 2008-02-12 CA CA2715367A patent/CA2715367C/fr not_active Expired - Fee Related
- 2008-02-12 JP JP2010546737A patent/JP5314053B2/ja not_active Expired - Fee Related
- 2008-02-12 ES ES08780411T patent/ES2383388T3/es active Active
- 2008-02-12 CN CN200880128704.XA patent/CN101998952B/zh not_active Expired - Fee Related
- 2008-02-12 SI SI200830675T patent/SI2250163T1/sl unknown
- 2008-02-12 PT PT08780411T patent/PT2250163E/pt unknown
-
2010
- 2010-08-08 IL IL207468A patent/IL207468A/en not_active IP Right Cessation
- 2010-08-10 ZA ZA2010/05700A patent/ZA201005700B/en unknown
- 2010-12-06 HK HK10111331.3A patent/HK1144935A1/xx not_active IP Right Cessation
-
2012
- 2012-05-23 HR HRP20120440AT patent/HRP20120440T1/hr unknown
- 2012-06-08 CY CY20121100523T patent/CY1112848T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1112848T1 (el) | 2016-02-10 |
| DK2250163T3 (da) | 2012-07-16 |
| AU2008350327B2 (en) | 2013-09-12 |
| KR20100114924A (ko) | 2010-10-26 |
| EP2250163B1 (fr) | 2012-03-28 |
| IL207468A (en) | 2015-11-30 |
| EA018782B1 (ru) | 2013-10-30 |
| HK1144935A1 (en) | 2011-03-18 |
| JP2011511832A (ja) | 2011-04-14 |
| MX2010008650A (es) | 2010-08-30 |
| SI2250163T1 (sl) | 2012-08-31 |
| CN101998952B (zh) | 2014-10-08 |
| BRPI0822335A2 (pt) | 2019-09-24 |
| JP5314053B2 (ja) | 2013-10-16 |
| ATE551337T1 (de) | 2012-04-15 |
| CA2715367A1 (fr) | 2009-08-20 |
| WO2009102318A1 (fr) | 2009-08-20 |
| IL207468A0 (en) | 2010-12-30 |
| NZ587323A (en) | 2012-02-24 |
| EA201001276A1 (ru) | 2011-04-29 |
| PL2250163T3 (pl) | 2012-10-31 |
| EP2250163A1 (fr) | 2010-11-17 |
| ZA201005700B (en) | 2012-01-25 |
| AU2008350327A1 (en) | 2009-08-20 |
| ES2383388T3 (es) | 2012-06-20 |
| PT2250163E (pt) | 2012-06-01 |
| KR101468765B1 (ko) | 2014-12-04 |
| CA2715367C (fr) | 2015-05-05 |
| CN101998952A (zh) | 2011-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120440T1 (hr) | Inhibitori virusa hepatitisa c | |
| HRP20160410T1 (hr) | Inhibitori hepatitis c virusa | |
| HRP20120706T1 (hr) | Imidazolil bifenil imidazoli kao inhibitori virusa hepatitisa c | |
| JP2013510853A5 (fr) | ||
| JP2012523415A5 (fr) | ||
| JP2012528161A5 (fr) | ||
| JP2011530531A5 (fr) | ||
| HRP20130063T1 (hr) | Inhibitori virusa hepatitisa c | |
| JP2010500415A5 (fr) | ||
| JP2013532725A5 (fr) | ||
| AR108411A2 (es) | Inhibidores del virus de la hepatitis c | |
| NZ600505A (en) | Hepatitis c virus inhibitors | |
| RU2355700C9 (ru) | Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с | |
| NZ594981A (en) | Hepatitis c virus inhibitors | |
| PE20160800A1 (es) | Combinacion de metil ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il-1-pirrolidinil)carbonil)-2-metilpropil)carbamato (daclatasvir) y n-(tert-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida (asunaprevir). | |
| EA022127B1 (ru) | Ингибиторы вируса гепатита с | |
| JP2013510857A5 (fr) | ||
| JP2010500414A5 (fr) | ||
| JP2012518000A5 (fr) | ||
| JP2010500413A5 (fr) | ||
| AR104566A2 (es) | Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo | |
| JP2012512169A5 (fr) | ||
| JP2010508362A5 (fr) | ||
| CA2536182A1 (fr) | Peptides macrocycliques actifs contre le virus de l'hepatite c | |
| EP2368900A3 (fr) | Inhibiteurs de sérine protéases, en particulier la HCV NS3-NS4A protéase |